IP Review

This publication includes IP covered under the following statements.

Copyright (c) Department of Health, Commonwealth of Australia.
Show Usage
- PBS Item Codes : EXPERIMENTALAUPSMedicationRequestApproachA , EXPERIMENTALAUPSMedicationRequestApproachB , EXPERIMENTALAUPSMedicationRequestApproachD and EXPERIMENTALAUPSMedicationRequestApproachE
HL7 Australia© 2018+; Licensed Under Creative Commons No Rights Reserved.
Show Usage
- IdentifierType AU : Bundle/ps-02 , Bundle/ps-03 ... Show 4 more
- DegreeLicenseCertificate AU : Bundle/ps-03 and Practitioner/guthridge-jarred
ISO maintains the copyright on the country codes, and controls its use carefully. For further details see the ISO 3166 web page: https://www.iso.org/iso-3166-country-codes.html
Show Usage
- ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code : DRAFTAUPatientSummaryImplementationGuide , EXPAUPSConsumer ... Show 25 more
The WHO grants a license for "commercial and non-commercial use" of ICD-11CC BY-ND 3.0 IGODetailed information can be found here: https://icd.who.int/en/docs/icd11-license.pdf Contact licensing@who.int to obtain further information.
Show Usage
- International Classification of Diseases, 11th Revision Mortality and Morbidity Statistics (MMS) : Condition/aci
This material contains content from LOINC . LOINC is copyright © 1995-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and is available at no cost under the license . LOINC® is a registered United States trademark of Regenstrief Institute, Inc.
Show Usage
- LOINC : Bundle/ps-02 , Bundle/ps-03 , Composition/ps-minimal , EXPERIMENTALAUPSComposition and Patient/banks-mia-leanne
This material contains content that is copyright of SNOMED International. Implementers of these specifications must have the appropriate SNOMED CT Affiliate license - for more information contact https://www.snomed.org/get-snomed or info@snomed.org .
Show Usage
- SNOMED Clinical Terms® (SNOMED CT®) : AllergyIntolerance/lactose-03 , AllergyIntolerance/noneknown ... Show 83 more
This material derives from the HL7 Terminology (THO). THO is copyright ©1989+ Health Level Seven International and is made available under the CC0 designation. For more licensing information see: https://terminology.hl7.org/license.html
Show Usage

hl7.fhir.us.hai: Healthcare Associated Infection Implementation Guide ®© HL7 | CC0 ( src )

DRAFT AU Patient Summary Implementation Guide for Testing, published by HL7 Australia. This guide is not an authorized publication; it is the continuous build for version 0.1.0-cibuild built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7au/draft-au-patient-summary/ and changes regularly. See the Directory of published versions ( src )

HL7 FHIR® Licensing and Legal Terms should also be referenced as the underlying standards published terms on which HL7 Australia FHIR Implementation Guides depend. ( src )

HL7® Governance and Operations Manual ( src )

HL7®, HEALTH LEVEL SEVEN®, FHIR® and the FHIR logo are trademarks owned by Health Level Seven International, registered with the United States Patent and Trademark Office. ( src )

International Healthcare Terminology Standards Developing Organization (IHTSDO). Where this specification includes or references content from SNOMED CT, which is copyright © 2002+ International Health Terminology Standards Development Organisation (IHTSDO) it is distributed by agreement between IHTSDO and HL7, or the Australian Digital Health Agency via NCTS terms. Implementer use of SNOMED CT is not covered by this agreement ( src )

Most trademarks used in conjunction with HL7® products, services and activities are registered and/or owned by HL7 International, rather than by HL7 Australia, and their use is subject to the associated HL7 International IP policies and licensing terms. ( src )

There are examples where a medication request may include the option of an oral dose or an Intravenous or Intramuscular dose. For example, "Ondansetron 8mg orally or IV twice a day as needed for nausea" or "Compazine® (prochlorperazine) 5-10mg PO or 25mg PR bid prn nausea or vomiting". In these cases, two medication requests would be created that could be grouped together. The decision on which dose and route of administration to use is based on the patient's condition at the time the dose is needed. ( src )

This implementation guide is provided to support the use of FHIR®© in an Australian context, and defines the minimum set of constraints on the FHIR resources to create the AU Core profiles. This implementation guide forms the foundation to build future AU Realm FHIR implementation guides and its content will continue to grow to meet the needs of AU implementers. (built Mon, Aug 4, 2025 13:28+0000+00:00) ( src )

This implementation guide is provided to support the use of FHIR®© in an Australian context. (built Tue, Aug 12, 2025 03:27+0000+00:00) ( src )

This material contains content from LOINC (http://loinc.org). LOINC is copyright © 1995-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and is available at no cost under the license at http://loinc.org/license. LOINC® is a registered United States trademark of Regenstrief Institute, Inc. ( src )

This material contains references to National Clinical Terminology Service artefacts these are Copyright © 2024 Australian Digital Health Agency, implementer user of this content are advised of the NCTS Terms of Use. ( src )

External References

Type

Reference

Content

web

Unattributed Code Systems

Copyright Fragment

Copyright and Registered Trademark Uses

External References

Internal Images